Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
About this item
Full title
Author / Creator
ELIXA Investigators , Pfeffer, Marc A , Claggett, Brian , Diaz, Rafael , Dickstein, Kenneth , Gerstein, Hertzel C , Køber, Lars V , Lawson, Francesca C , Ping, Lin , Wei, Xiaodan , Lewis, Eldrin F , Maggioni, Aldo P , McMurray, John J.V , Probstfield, Jeffrey L , Riddle, Matthew C , Solomon, Scott D and Tardif, Jean-Claude
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent cardiovascular event did not alter the rate of subsequent major cardiovascular or other serious adverse events.
Randomized trials involving patients with new or established type 2 diabete...
Alternative Titles
Full title
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1744662612
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1744662612
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1509225
